COMP <GO>
IDXG vs RTX // EV/EBITDA & P/E VALUATION
Interpace Biosciences Inc. (NASDAQ) VS. RTX Corporation (NYSE) • 15-METRIC TALLY: IDXG 4
— RTX 5
▲ EV/EBITDA & P/E VALUATION LEADER: IDXG
LAST: $5.72 (+15.56%) • MKT CAP: $23.2M
valuation
4.7x
LAST: $199.40 (+1.82%) • MKT CAP: $269.08B
valuation
26.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IDXG VS. RTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IDXG | RTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 62.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.20% | 7.20% | +9.00 | IDXG | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 4.7x | 26.5x | -21.80 | IDXG | /valuation <GO> |
| Free Cash Flow Yield | 23.60% | 2.95% | +20.65 | IDXG | /fcf-yield <GO> |
| Operating Margin | 10.50% | 10.50% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | 63.50% | 7.60% | +55.90 | IDXG | /net-margins <GO> |
| Revenue Growth (YoY) | -17.50% | 9.70% | -27.20 | RTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 1.33% | -1.33 | RTX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.73 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | RTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.0 | 60.0 | -10.05 | RTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 37.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $23.2M | $269.08B | -$269.06B | RTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IDXG REV | RTX REV | IDXG GROSS % | RTX GROSS % | IDXG FCF | RTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $38.7M | $88.60B | 62.3% | — | $5.5M | $7.94B |
| FY 2024 | $46.9M | $80.74B | 63.8% | — | $3.8M | $4.53B |
| FY 2023 | $40.0M | $68.92B | — | — | $3.8M | $4.78B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IDXG // BETA —
RTX // BETA 0.92